News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UCB Japan Co., Ltd. To License H2-Receptor Antagonist STOGAR tab. To Korean Pharmaceutical Boryung Pharmaceuticals Co., Ltd.


10/19/2005 5:08:45 PM

Tokyo (JCNN) - UCB Japan announced on June 7 that it has signed an agreement with Korean company Boryung Pharmaceutical, whereby Boryung will exclusively license to sell in Korea STOGAR tab. 5 and STOGAR tab. 10, H2 receptor antagonists UCB Japan manufactures and sells in Japan. Launched in April 2000, H2 receptor antagonist STOGAR tab. has been used in the treatment of gastritis and peptic ulcer.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES